Possible scenario
Scientific Skepticism Returns
20% Chance
Investors and agencies may conclude that the AI-pathogen antibody narrative is compelling but still technically early. If preclinical data, validation assays, or safety benchmarks lag expectations, enthusiasm narrows to a smaller set of specialist backers.
Secondary impacts
- Healthcare -0.3%
Tickers
- GENB-0.9%
- ABSI-0.8%
- RXRX-0.6%
- DNA-0.5%
Portfolio impact
S&P 500-0.0%
Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.
Keeping an eye on this scenario?
Tilt can alert you when its probability or impact shifts, or send you a recommendation when it crosses a threshold.